retatrutide clinical trials latest FDA Approval Status 2026: Everything We Know So Far Retatrutide, an investigational triple hormone

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM

Dosing regimens in studies are tightly controlled and vary based on the research design, but generally vary between 18 mg weekly, in increments of 1mg with a maximum dose of 812mg

Golden era bodybuilders recognized its unique hardening effects decades before modern research explained the mechanisms

The inclusion of glucagon receptor engagement distinguishes Retatrutide vs Tirzepatide at the receptor level

People with a family history of medullary thyroid carcinoma (a type of thyroid cancer) or those with Multiple Endocrine Neoplasia syndrome type 2 should also avoid Semaglutide due to the potential risk of thyroid tumors